420 with CNW — New York’s Recreational Cannabis Market Faces Hurdles

In April 2021, New York legalized recreational cannabis sales for people aged 21 and older, becoming the 15th state in the country to approve adult-use cannabis sales. Eligible New Yorkers would now be able to possess up to three ounces of cannabis or 24 grams of concentrates with no legal repercussions.

While the legislation didn’t outline a specific schedule for recreational sales, they were expected to begin sometime in 2022. Lawmakers behind the bill and reform advocates predicted that the move to legalize adult-use marijuana in New York could prove to be extremely lucrative, creating a market worth an estimated $4.2 billion and surpassing most other states with recreational markets.

An estimated 40% of the tax revenue generated from recreational cannabis sales in New York would be allocated to Black and Brown communities that had been disproportionately affected by the war on drugs.

However, it will be quite a while before New York’s recreational cannabis industry reaches the heights lawmakers and activists dream of. For starters, we still don’t know when dispensaries will open their doors and begin sales, and entrepreneurs are still waiting eagerly for word from regulators.

Office of Cannabis Management spokesperson Aaron Ghitelman conceded that the state needed more than one recreational cannabis dispensary and that the office was working to approve more stores. New York is currently home to only one dispensary. The Housing Works Cannabis Co. opened its doors for just a few hours on December 29. New York Office of Cannabis Management executive director Chris Alexander made the first ceremonial purchase of the day, buying 100 milligrams of THC gummies and an eighth-ounce of locally grown cannabis flower.

While this was undoubtedly great, a single store is far below the 20 stores that Governor Kathy Hochul had promised before the start of the year. Housing Works Cannabis Co. sold to more than 500 customers in the first four hours after it opened its doors, signifying the immense demand for recreational cannabis among New Yorkers.

Conversely, sales in nearby New Jersey began last April with around 12 operational locations.

It is still unclear when state regulators will allow other adult-use cannabis retailers to open their doors. Furthermore, New York is still plagued by a massive illicit cannabis market, an issue that also affects states such as California that are among the largest cannabis markets in the world.

Alexander pledged to provide more law enforcement to handle New York’s cannabis black market in the wake of numerous cease and desist letters and raids of unlicensed cannabis operations by police and the New York City Sheriff.

As the legal production of adult-use cannabis grows, there is likely to be a bigger market for indoor cultivation equipment, such as that made by Advanced Container Technologies Inc. (OTC: ACTX), as players compete to carve out for themselves a segment of this new market.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

REZYFi, Inc. Leverages Cannabis and Real Estate Financing Opportunities Through Wholly-Owned Subsidiaries

The growing perception is that cannabis companies investing in real estate raise the value of the area in which they invest
A 2020 study conducted in states where medicinal and recreational cannabis is legal found that 35-36% of respondents saw an increase in demand for warehouses, 23% for storefronts, and up to 28% for land
The global legal cannabis market was valued at $17.8 billion in 2021 and is expected to reach $134.4 billion by 2030
REZYFi is leveraging its corporate strengths through two wholly-owned subsidiaries – REZYFi Lending and ResMac Inc. – offering a diversified approach to cannabis and real estate financing that traditional banks are reticent to offer

Cannabis and real estate have a unique relationship. The growing perception on the market is that cannabis companies investing in real estate raise the value of the area they invest in. Three strong arguments support the perception – abandoned buildings are gaining new life when rehabilitated by cannabis businesses, entrepreneurs are investing in the cannabis market as an asset that does not depreciate over time, and new jobs are increasing residential home sales. In a 2020 study conducted in states where cannabis for medicinal and recreational purposes is legal, 35 to 36% of respondents noted an increase in demand for warehouses, 23% for storefronts, and up to 28% for land (https://cnw.fm/6DypS).

At the forefront of cannabis and real estate is REZYFi, a growth mortgage origination and specialized financing company in the United States. REZYFi originates, structures, and invests in first mortgage loans and alternative structured financing secured by commercial real estate properties. The company’s target market includes licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing.

The global legal cannabis market was valued at $17.8 billion in 2021 and is expected to grow to $134.4 billion by 2030, growing at a CAGR of 25.3%. The market is expected to grow due to the increase in the legalization of cannabis and the acceptance of its use in the medical industry. The FDA has issued several guidelines, and new policies are underway to regulate the use of cannabis – ultimately driving investment in the cannabis industry (https://cnw.fm/x83lx).

REZYFi operates through two wholly-owned subsidiaries and is positioned as one of the first cannabis mortgage bankers in the United States, an area most traditional banks are hesitant to serve. REZYFi Lending primarily addresses emerging real estate-related financing opportunities, leveraging a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. ResMac Inc. has been operating for 13 years and is the company’s traditional mortgage origination, correspondent, and servicing operation. REZYFi expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination during the same period.

REZYFi is using a diversified approach to the real estate lending sector to capitalize on growth in multiple verticals in the years to come. The company’s experience, network of independent brokers, and proprietary technology allow it to leverage the industry and offer a wide range of real estate and financing options that were not readily available. As of December 2022, the company is licensed in 36 states and plans on expanding to all states in the future.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family
This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries
In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancers
This patent inches Lexaria closer to taking advantage of the cosmeceuticals market, projected to hit $95.95 billion by 2030, and the global skincare market that is estimated to post a CAGR of 4.6% over the forecast period (2021-2030)

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced its 28th granted patent worldwide and the first granted patent from its sixth patent family, titled “Transdermal And/Or Dermal Delivery Of Lipophilic Active Agents.” The Canadian patent #3,093,414 is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), all established on the company’s patented DehydraTECH technology (https://cnw.fm/cMrMY).

This patent comes three months after Lexaria was granted its 27th worldwide patent in Mexico and just eight months since it was awarded its 25th patent in the United States for “Compositions and Methods For Enhanced Delivery of Antiviral Agents.” It joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of DehydraTECH formulations remain pending in many other countries.

“This will be our 25th patent granted worldwide and another validation of the versatility of our DehydraTECH drug delivery technology,” noted Chris Bunka, Lexaria’s CEO, during the announcement of the company’s first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs (https://cnw.fm/doNmo).

In Lexaria’s 2018 study, DehydraTECH-CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancements. When pitted against the best-performing commercial penetration enhancer, DehydraTECH-CBD still proceeded to be 225% more effective at penetration through the skin, making it the fastest for absorption into the epidermis, dermis, and through the skin.

The cosmeceuticals market is projected to hit $95.75 billion by 2030, up from $45.56 billion in 2021. In addition, the global skincare market is estimated to post a CAGR of 4.6% by 2030, up from $130.5 billion in 2021 (https://cnw.fm/Nz4ww). Lexaria recognizes the opportunity therein. This patent inches the company closer to taking advantage of this booming market, allowing it to curve out a niche for itself and establish a market presence, mainly bolstered by its patented DehydraTECH technology.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Report from White House Draws Attention to Law Enforcement Concerns on Marijuana

Cannabis policing has been an extremely controversial issue in American history. While the war on drugs was ostensibly launched to cripple the criminal organizations behind the illicit drug trade, Black and Brown communities were disproportionately affected by the antidrug campaign. Decades later, the drug war has decimated marginalized communities for minor drug charges and has long been declared an unmitigated failure.

Even though the move to legalize cannabis across the country has been praised by criminal and racial justice activists, the cannabis reform movement hasn’t received everyone’s support. The White House recently issued its annual drug enforcement report to Congress and highlighted several concerns that law enforcement has regarding America’s growing state-level cannabis industry. For instance, the report outlined police concerns about burglaries and robberies in states with legal cannabis markets.

Although cannabis is now legal in more than 30 states, it remains a controlled substance at the federal level. This has largely prevented the state-legal cannabis industry from accessing crucial financial services, such as banking and cashless payment systems, forcing it to operate on a mostly cash-only basis.

Unfortunately, this has made cannabis dispensaries an attractive mark for criminals looking for establishments with plenty of physical cash and movable product on hand. In 2022, an explosion of cannabis dispensary robberies led to increased calls for a cannabis banking bill that would finally grant the industry access to cashless payment services.

The report also stated that despite legalization efforts across the country, the illicit marijuana market is still going strong and supplying a large chunk of the cannabis in America. Some pundits expected that legalization efforts across the country would slow down the illicit market, but the state-legal cannabis industry has largely been unable to compete.

On top of denying states tax revenue from cannabis production and sale, the report added that illicit cannabis growers posed a “serious environmental threat.” The report observed that illegal grows polluted water sources and poisoned wildlife through the unregulated use of pesticides, herbicides and fertilizers.

However, legalization experts have long argued that these reports are biased because they are facilitated through the White House Office of National Drug Control Policy (ONDCP), whose statutory mandate is opposing the legalization of controlled drugs such as cannabis.

Marijuana Policy Project (MPP) president Toi Hutchison stated that prohibition is the reason for large-scale illegal cannabis farming, not legalization. She argued that there is little to no illicit production of drugs such as alcohol and tobacco because they are legal under both state and federal law.

In addition, Hutchison noted that prohibition made illicit production more attractive because it drove up production costs and made it almost impossible to compete with illicit sellers.

As more companies such as India Globalization Capital Inc. (NYSE American: IGC) move toward medicalizing cannabis compounds, the discussion on this plant will broaden as growing numbers of people seek FDA-approved treatments made from this divisive substance.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — US Border Patrol Sees 95% Drop in Cannabis Seizures as Legalization Spreads

Marijuana seizures at the borders dropped significantly in 2022, an implementation shift that solicitors attribute to the legalization movement at the state level. Border marijuana confiscations have dwindled drastically in the last 10 years, from 2million pounds in 2012 to a little more than 150,000 pounds in 2022.

Several factors may possibly explain this, including one being a shift in priorities for the enforcement agencies, though experts deem the trend as reduced demand for smuggled illicit cannabis as more states moved to legalize cannabis. In 2014, maiden recreational marijuana shops were opened in Colorado and Washington, starting a reform currently being implemented in 21 U.S. states for adult-use legalization.

In the initial two months of FY 2023, officers seized 17,000 pounds of cannabis, with their November tally being the lowest amount captured at a little more than 7,000 pounds. Surprisingly, in the same month in 2020, officers arrested individuals for possession of close to 62,000 pounds of marijuana.

Also, aligning with other studies, the reports showed a significant reduction in cannabis seizures at checkpoints since 2016 where there were 70,000 pounds of marijuana seized by the border authorities, in comparison to 31,000 pounds in 2020.

The Uniform Crime Reporting (UCR) system of the FBI shows a significant drop in cannabis drug busts at the local and state level even as more states enact reform. However, the validity of FBI’s data has been questioned over the alleged confusion among enforcement agencies on how to report this.

In last year’s report, the Congressional Research Service said that the spread of legal cannabis together with efforts on the international reform side reduced the demand for illicit marijuana specifically from Mexico.

In its budget performance summary for FY 2023 given to Congress, the Drug Enforcement Administration acknowledged that as the production of marijuana goes up in the United States, it is frustrating the trafficking of illicit cannabis across the southern border (Mexico). Research published in 2018 by Cato Institute also discovered that legalizing marijuana at the state level greatly undermined the smuggling of marijuana.

As more and more states vote to legalize cannabis, marijuana cases on the federal front also have been on a downward spiral. This was part of a report released last year by the Sentencing Commission of the United States (USSC). Also, drug-related crimes that were prosecuted federally increased in 2019, but marijuana cases dropped, according to a report released by Supreme Court Chief Justice John Roberts at the end of last year.

As legalization spreads to more states in the coming years, the demand for financing from entities such as REZYFi Inc. is likely to grow as licensed companies work to meet the demand generated in those newly launched cannabis markets.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi, Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how,” said Eric A. Adams, InMed president and CEO. “Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed was able to advance its programs and achieve a number of key milestones. As we move forward into 2023, we are very encouraged by the strength of our pharmaceutical programs, with several material milestones anticipated in the coming quarters.”

To view the full press release, visit https://cnw.fm/KK52u

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — GOP Congresswoman Files Measure to Amend IRS Code So Cannabis Businesses Can Obtain Tax Relief

Last week, a legislation that would allow legal and licensed operators in the cannabis industry to receive federal tax deductions that are offered to other businesses was introduced in Congress. The bill, which was introduced by Representative Nancy Mace, seeks to revise section 280E of the Internal Revenue Service code.

Section 280E prohibits businesses involved in activities comprised of trafficking in substances classified under the Controlled Substances Act such as marijuana, from receiving tax credits or deducting expenses from their taxes. This is despite the fact that these entities are still required to pay taxes like other businesses.

This section was enacted more than four decades ago to stop drug traffickers from writing off expenses on their taxes. Today, it is applied to state-legal cannabis cultivators, processors and stores, which significantly increases the tax rates of these businesses, in comparison to companies in other industries.

Legislators have, in previous sessions, tried to change the provision to allow state-legal cannabis businesses to be treated like businesses in other markets. However, Since the bill was introduced with only days left in the previous session, it will have to be reintroduced in the next session of Congress.

The last version of the legislation was sponsored by Representative Earl Blumenauer, who also sponsored the SAFE Banking Act. This bill has been cleared by the House more than five times, with many hopeful that its approval would fix some issues in the cannabis industry. However, it was not enacted after stalling in the Senate once again.

This comes as states such as Pennsylvania and New Jersey continue to offer some tax and banking relief for marijuana industry operators in their jurisdictions. As a whole, however, the cannabis industry continues to face challenges caused by prohibition.

The only guidance the Internal Revenue Service has provided explains that while marijuana businesses can’t apply for standard deductions, Section 280E doesn’t prohibit these businesses from decreasing their gross receipts by properly calculating cost of goods sold to determine their gross income.

This update was issued in response to a report by the Treasury Department, which saw the inspector general for tax administration criticizing the IRS for not sufficiently advising taxpayers operating in the cannabis industry on federal tax law compliance. The treasury report also directed that the IRS offer guidance for the cannabis industry.

Congresswoman Mace wasn’t the only Congress member to file a bill to reform drug policy with a few days left in the last session. Representative Matt Gaetz also reintroduced a measure to promote studies of cannabis. He has filed the legislation in previous sessions.

If these reforms to the federal tax code are passed, it could potentially make a big difference to the bottom lines of marijuana companies such as Flora Growth Corp. (NASDAQ: FLGC) because of the tax relief secured.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Six Marijuana Trends to Watch for in 2023

There is an air of optimism at the turn of every new year, and the marijuana industry isn’t left behind. Cannabis business moguls are optimistic that profitable trends shall emerge for the industry’s fiscal year 2023.

Last year saw some lows for the industry, from limited capital lending and investment to inflation and other factors. The new year starts with great hopes for the industry, and the market can look for several trends as the year progresses. Some 2023 trends to look out for in the cannabis industry include the following:

Key market consolidation

The COVID-19 business boom created the analogy that the cannabis industry cannot suffer a recession. However, Colorado and Washington are grappling with falling prices as Michigan and Massachusetts markets are saturating. This has caused employee layoffs to cut costs. Incidentally, mergers and acquisitions have significantly gone down as capital lending for cannabis entrepreneurs has decreased. The new year is likely to see plenty of consolidation in the industry.

Delta-8 THC stands its ground at the industry’s helm

Most state markets sought to tether the delta-8 THC wave in 2022 because unregulated products skyrocketed bringing stiff competition for licensed traders. The 2018 farm bill legalized hemp production in the United States if the plant where the hemp was produced met the lawful definition of hemp. This year is likely to bring a lot of activity in terms of laws to regulate delta-8 THC products.

Segmentation of product vis-à-vis consumer polished tastes at retail level

Marijuana flower sales continue to increase in all markets, but this may have to pave the way for vapes, concentrates and edibles as consumers acquire new tastes and habits. Infused pre-rolls sales have increased, and vapes have returned, ranking as the second-best-selling product in the space.

Struggle by New York market after introduction of recreational cannabis

Unlicensed entrepreneurs are popping up kiosks and clinics trying to sell cannabis, a threat to the licensed market. In a bid to discourage consumers from purchasing from illicit traders, the state needs to create friendly conditions and low taxes for businesses to encourage more traders to formalize their companies. This would help create a safe and healthy playground for both entrepreneurs and consumers.

Canadian cannabis companies’ woes may be sliced

Canadian companies have been trading cannabis at a loss in a bid to undermine their competitors. This trend might die out if Wall Street funding dries up. Canadian farmers are producing cannabis in excess, causing some shops to close in states where the market is already oversaturated. With a reduction in financing, selling at subsidized prices will end, forcing companies to find better ways to stand out on the market.

Continuous success of unionization endeavors

This will continue moving forward given that the cannabis industry stands as the largest in the United States with potential for increased growth. Even in Canada where some industrial action has taken place, unionization is likely to pick up pace.

As these developments take shape, it would be interesting to follow how ancillary companies such as Advanced Container Technologies Inc. (OTC: ACTX) fare in response to the direction the marijuana industry takes.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidly growing house of brands building customer bases and distribution channels across international lines as it aims to distinguish itself within a highly competitive arena. “Much of Flora Growth’s strength lies in its licensed cultivation, extraction and isolation facility located in northern Colombia’s fertile climate, where an experienced labor force is helping the nation emerge from decades of drug war illicit trade into a recognized and regulated market,” a recent article reads. “From its 247 acres of growing fields, the company’s harvests move into a production pipeline that includes a flower and derivatives production lab situated within the cultivation camp, as well as a topical, capsules and dietary supplements lab in Colombia’s capital and a third lab in the United States, where CBD ingestible, tinctures and gummies are made. A fourth state-of-the-art lab being built in Colombia’s capital is being designed to formulate custom and proprietary pharmaceuticals that will be sold and used in Colombia. The life sciences lab is expected to open by the end of this year with eight registered pharmaceutical grade formulas that target specific ailments such as insomnia, epilepsy and anxiety.”

To view the full article, visit https://cnw.fm/QWUen

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands, designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients

Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs
In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure
The company also reported that it had demonstrated superior CBD blood absorption levels in its HYPER-H21-4 study from DehydraTECH-CBD relative to those of published comparators
At the lowest (3.38 mg/kg) and highest (4.46 mg/kg) dose levels tested, DehydraTECH-CBD resulted in 45.8% and 133.4% higher average blood plasma levels, respectively, than the figure reported when a higher (5 mg/kg) dose level of non-Lexaria, pharmaceutical-grade CBD was administered

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a proprietary platform technology that is capable of delivering certain drug molecules more effectively into the human body than their generic forms. That, CEO Chris Bunka contends (https://cnw.fm/FEXdl), allows for various efficiencies and decreases in adverse side effects.

Known as DehydraTECH(TM), the patented technology can be easily incorporated into the formulation and manufacturing processes of existing or new orally ingestible and topical products, according to the company, provided the products are fat soluble. So far, Lexaria has been able to process various active molecules and drugs, including antiviral drugs, nicotine, cannabidiol (“CBD”), vitamins, phosphodiesterase inhibitors, and more, using its DehydraTECH platform technology (https://cnw.fm/Sim8u). Moreover, the company has, as of December 29, 2022, received a total of 28 patents granted worldwide (https://cnw.fm/9C6eR) for several DehydraTECH-processed applications.

But what is even more remarkable is the fact that Lexaria has evidenced, through multiple animal and human studies, that its DehydraTECH platform technology increases bio-absorption by up to 10x, reduces the time of onset from as much as 1-2 hours to just minutes, delivers drugs more effectively into the bloodstream, and masks unwanted tastes. And in what adds to the company’s repository of the proven benefits of DehydraTECH, the company recently completed a randomized, double-blinded, placebo-controlled cross-over study of 66 male and female volunteers, its most comprehensive hypertension study yet.

Dubbed HYPER-H21-4, the study showed that DehydraTECH-processed CBD had an exceptional safety and tolerability profile. It also evidenced that the formulation resulted in a statistically significant lowering of 24-hour ambulatory blood pressure (“BP”), with the BP lowered for the entire five-week study duration. Furthermore, the BP lowered both for patients not taking any other antihypertensive drugs as well as those currently on antihypertensive medication (https://cnw.fm/TTxMQ).

At the time of announcing the results from this study, the company on October 27 stated that “additional study endpoint analyses as described in the complete study protocol are still underway and any relevant material findings will be reported upon in due course….” And in a December 21 news release, Lexaria reported on one of these findings.

According to this recent announcement, Lexaria reported that it had demonstrated superior CBD blood absorption levels from its patented DehydraTECH-CBD compared to those of published comparators. In their analysis, Lexaria’s researchers compared the average blood plasma levels of DehydraTECH-CBD at various dose levels (after the steady state or the amount of time needed before a consistent dose of drug achieves a stable plasma level had been reached) with that of non-Lexaria, pharmaceutical-grade CBD formulations published in two studies – a 2017 clinical trial and a 2019 study (https://cnw.fm/XGBhH).

The 2017 trial evidenced an average blood plasma CBD level of 23.0 ng/ml after 22 days (the steady state) of daily dosing at a 5 mg/kg non-Lexaria CBD dose level. Lexaria’s HYPER-H21-4 study, on the other hand, showed that the DehydraTECH technology resulted in a 45.8% higher average blood plasma level (33.3 ng/mL) at DehydraTECH-CBD’s lowest dose level tested of just 3.38 mg/kg. When the dose level was increased to 4.46 mg/kg (the highest in the test), the blood plasma level was 133.4% higher than in the 2017 study at 53.7 ng/mL.

On their part, the researchers in the 2017 study evaluated higher CBD dosing at a level of 10 mg/kg, showing a blood plasma level of 62.1 ng/mL. Lexaria’s HYPER-H21-4 study, however, did not see the need to administer a dose as high as 10 mg/kg, with the researchers instead extrapolating the administered dose levels linearly to 10 mg/kg. According to the resulting data trend, a 10 mg/kg dose of DehydraTECH-CBD would result in a plasma level of 149.5 ng/mL, a 141% improvement over the findings contained in the 2017 study.

Using the extrapolated data trend, Lexaria also showed that at a dose level of 10 mg/kg, the absorption resulting from the administration of DehydraTECH-CBD would outperform that of the pharmaceutical-grade, synthetic CBD formulation used in the 2019 study. The non-Lexaria synthetic CBD, the 2019 study showed, reached a blood plasma level of 91 ng/mL. By comparison, Lexaria’s linear extrapolation showed that DehydraTECH-CBD absorption would outperform this figure by 64%.

“DehydraTECH-CBD has repeatedly shown that it can be administered at much lower dose levels than other CBD formulations to achieve effective levels within the bloodstream, as supported by this pharmaceutical-industry peer comparison,” commented Bunka. “This is extremely important to patients hoping to achieve positive health outcomes while using lower levels of medication with no serious side effects and also important to Lexaria as we pursue FDA registration of DehydraTECH-CBD.”

Lexaria hopes to file an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) this year in anticipation of possible approval to proceed with registered clinical trials evaluating the safety, tolerability, and effectiveness of DehydraTECH-CBD in treating hypertension.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.